SCHEMBL2368002

SCHEMBL2368002

O=S(=O)(Nc1cccc2c1[nH]c1ccccc12)c1cccc(C(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
GAA P10253 1/20 0.58
CLK1 P49759 1/20 0.58
PTGES2 Q9H7Z7 2/20 0.55
LMNA P02545 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
SLC40A1 Q9NP59 1/20 0.53
ACLY P53396 1/20 0.53
PARP14 Q460N5 2/20 0.52
CKS1B P61024 1/20 0.51
SKP2 Q13309 1/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
BRAF P15056 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7592771 0.83 MEN1 (0.74) MEN1KMT2AGAACLK1PTGES2
SCHEMBL7491194 0.81 BRD4 (0.57) MEN1KMT2ASLC40A1ACLYPARP14
SCHEMBL7572582 0.81 CLK1 (0.67) MEN1KMT2AGAACLK1PTGES2
SCHEMBL2367200 0.81 CLK1 (0.53) MEN1KMT2AGAACLK1PTGES2
SCHEMBL10143421 0.79 MEN1 (0.66) MEN1KMT2AGAACLK1PTGES2
SCHEMBL7572596 0.78 MEN1 (0.67) MEN1KMT2AGAACLK1PTGES2
SCHEMBL10585396 0.77 PTGES2 (0.66) MEN1KMT2AGAACLK1PTGES2
SCHEMBL10622385 0.77 MEN1 (0.66) MEN1KMT2AGAACLK1PTGES2
SCHEMBL7572994 0.76 SLC40A1 (0.66) MEN1KMT2AGAACLK1PTGES2
SCHEMBL5949363 0.76 KEAP1 (0.61) MEN1KMT2ALMNANPSR1SLC40A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2366687-B1 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO LTD (CN) 2015-11-04 EP disclosed
EP-2366687-B1 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO LTD (CN) 2015-11-04 EP disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
US-8173693-B2 Benzenesulfonamide derivatives and pharmaceutical composition thereof PURZER PHARMACEUTICAL CO., LTD. (TW) 2012-05-08 US disclosed
CN-102199148-A Benzenesulfonamide derivatives and pharmaceutical compositions thereof PURZER PHARMACEUTICAL CO LTD 2011-09-28 CN disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof PURZER PHARMACEUTICAL CO., LTD. (TW) 2011-09-22 US disclosed
EP-2366687-A2 Benzenesulfonamide derivatives and pharmaceutical composition thereof Purzer Pharmaceutical Co., Ltd. (CN) 2011-09-21 EP disclosed
EP-2366687-A2 Benzenesulfonamide derivatives and pharmaceutical composition thereof Purzer Pharmaceutical Co., Ltd. (CN) 2011-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230651-A1 Benzenesulfonamide derivatives and pharmaceutical composition therof CCNI, CCNE1, CCND1 MEN1 3009/4885KMT2A 2829/4885GAA 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.